Total Synthesis of (−)-Caprazamycin A by Nakamura, Hugh et al.
Title Total Synthesis of (－)-Caprazamycin A
Author(s)Nakamura, Hugh; Tsukano, Chihiro; Yasui, Motohiro;Yokouchi, Shinsuke; Igarashi, Masayuki; Takemoto, Yoshiji




This is the peer reviewed version of the following article: Hugh
Nakamura, Chihiro Tsukano, Motohiro Yasui, Shinsuke
Yokouchi, Masayuki Igarashi, Yoshiji Takemoto, Total
Synthesis of (－)-Caprazamycin A, Angewandte Chemie, 127,
10, (3179-3182), (2015) which has been published in final form
at https://doi.org/10.1002/ange.201411954. This article may be
used for non-commercial purposes in accordance with Wiley
Terms and Conditions for Use of Self-Archived Versions.; This






Total Synthesis of (−)-Caprazamycin A** 
Hugh Nakamura, Chihiro Tsukano, Motohiro Yasui, Shinsuke Yokouchi, Masayuki Igarashi and Yoshiji 
Takemoto* 
 
Abstract: Caprazamycin A has significant antibacterial 
activity against Mycobacterium tuberculosis (TB). The first 
total synthesis is herein reported featuring (i) the scalable 
preparation of the syn-β-hydroxy amino acid with a 
thiourea-catalyzed diastereoselective aldol reaction, (ii) 
construction of a diazepanone with an unstable fatty acid 
side chain, and (iii) global deprotection with hydrogenation. 
This report provides a route for the synthesis of related 
liponucleoside antibiotics with fatty acid side chains. 
 
Caprazamycin A (1) was isolated from Streptomyces sp. 
MK730 62F2 and is a liponucleoside characterized by a 
seven-membered diazepanone core with an amino ribose, a 
uridine and a fatty acid side chain (Figure 1).1 Several 
analogs isolated by Igarashi et al. in 2003 share these 
features. Caprazamycins have antibacterial activity against 
Mycobacterium tuberculosis (TB), including 
multidrug-resistant TB (MDR-TB). Biological studies 
showed that it is an inhibitor of the peptidoglycan 
biosynthetic enzyme MraY.2 MraY is essential for bacterial 
cell growth and is biosynthetically located upstream of an 
enzyme targeted by β-lactam and glycopeptide antibiotics 
(e.g. vancomycin). New antimicrobial agents targeting 
MraY are expected to be active against vancomycin- and 
methicillin-resistant Staphylococcus aureus (VRSA and 
MRSA).3 Recently, CPZEN-45, which exhibits more potent 
activity against TB‒‒including extensively 
multidrug-resistant TB (XDR-TB), has been developed 
based on caprazamycins.2b,4  
The complex structure and significant biological 
activities of caprazamycins have drawn much attention from 
synthetic chemists.5,6 Matsuda and Ichikawa accomplished 
the first total synthesis of palmitoyl caprazol and caprazol 
(2), which does not possess a fatty acid side chain.7 
Shibasaki and Watanabe recently reported the synthesis of 2 
and the fatty acid side chain.8 However, a total synthesis of 
the caprazamycins has not yet been reported, because of the 
difficulty in introducing an unstable fatty acid side chain. 
This has also hampered the total synthesis of related 
liponucleoside antibiotics, such as liposidomycin C (3).9 
Therefore, we initiated a caprazamycin A (1) synthetic 
project, which would also be applicable to related natural 
products.  
Figure 1. Caprazamycin A (1), caprazol (2) and liposidomycin C (3). 
It is challenging to introduce the side chain containing 
unstable structures. To access caprazamycin A (1), it was 
envisioned that unstable side chains 4 and 5 could be 
introduced to protected caprazol 6 as the final step. This 
would be followed by global deprotection without adversely 
affecting any functional groups (Scheme 1). Benzyl (Bn), 
carboxybenzyl (Cbz) and benzyloxymethyl (BOM) 
protecting groups were selected and are readily removed by 
Pd-catalyzed hydrogenation. Protected 6 was prepared using 
(i) the Mitsunobu reaction to construct the seven-membered 
diazepanone, and (ii) a diastereoselective aldol reaction of 
isocyanate 8 and aldehyde 9 with thiourea catalyst 10 to 
obtain syn-β-hydroxy amino acid derivative 7.10 
 
 
Scheme 1. Retrosynthesis of caprazamycin A (1). 
Fatty acid side chains 4 and 5 were first prepared. 
β-Siloxy carboxylic acid 4 was synthesized from acid 
chloride 11 via the modified Noyori asymmetric reduction11 
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of β-ketoester 1212 (Scheme 2). Enantioselective 
desymmetrization of 3-methyl glutaric anhydride 13 using 
cinchona alkaloid catalyst 14 with Song’s procedure13 gave 
carboxylic acid 15 with high enantioselectivity (92% ee). 
Condensation of 15 with L-rhamnose derivative 16,14 
followed by removal of the benzyl group of ester 17 with 
hydrogenolysis gave carboxylic acid 5. 
 
 
Scheme 2. Synthesis of fatty acid side chains 5 and 6. Reagents and conditions: a) 
BnOAc, LDA, THF, −78 °C, 51%; b) H2, (S)-BINAP-RuBr2 (4.0 mol%), MeOH, 
50 °C, 48%, 94%ee for two steps; c) TESOTf, 2,6-lutidine, CH2Cl2, 0 °C, 94%; d) H2, 
10% Pd/C, EtOAc, 25 °C, 92%; e) BnOH, catalyst 14 (10 mol%), CPME, 86%, 92% 
ee.; f) Ghosez reagent, CH2Cl2, 0 °C, then nBuLi, THF, 48%; g) H2, 10% Pd/C, EtOAc, 
25 °C, 92%. LDA = lithium diisopropylamide, CPME = cyclopentyl methyl ether, 
Ghosez reagent = 1-chloro- N,N,2- trimethylpropenylamine. 
Construction of the syn-β-hydroxy amino acid moiety 
with S configuration at C5’ was then investigated. Several 
strategies have been employed for this in the past,5d,e,6g,i-k,7a,8a 
two of which were for the total synthesis of caprazol. One is 
Sharpless’ asymmetric aminohydroxylation of the 
α,β-unsaturated ester7a and the other is the diastereoselective 
isocyanoacetate aldol reaction.8a We anticipated that the 
stereochemistry at C5’ could be controlled with a novel 
diastereoselective aldol reaction using isocyanate 8 in the 
presence of an organocatalyst.10  
Initially, aldehyde 915 was treated with 8 and Et3N (10 
mol%) in toluene to give a mixture of aldol adducts 18a and 
18b in 50% yield with poor diastereoselectivity (1:1.8) 
(Table 1, Entry 1). In contrast, treatment with (S,S)-thiourea 
catalyst 10a (10 mol%) in toluene gave desired aldol adduct 
18a as the major product in 64% yield (3.1:1), along with a 
small amount of byproduct 19 (Entry 2). The selectivity was 
improved to 6.5:1 by changing to (S,S)-thiourea catalyst 10b 
(10 mol%) (Entry 3). Formation of byproduct 19 was 
suppressed by reducing the amount of catalyst (7 mol%) 
(Entry 4). Use of (R,R)-thiourea catalyst 10b (10 mol%) 
gave undesired diastereomer 18b in 80% yield with high 
selectivity (>20:1) (Entry 5). This protocol was also applied 
to the large scale synthesis of aldol adduct 18a. 
Aldol adduct 18a was converted to syn-β-hydroxy 
amino acid derivative 7 in good yield by regioselective 
decarboxylation and transesterification of the resultant 
thermodynamically stable trans-oxazolidinone in the 
presence of zinc cluster Zn4(OCOCF3)6O (Scheme 3).16 The 
minor isomer was removed during these transformations. 
Following Matsuda and Ichikawa’s procedure,7 fluoride 21 
underwent β-selective glycosylation, reduction of the azido 
group, Cbz protection and hydrolysis under basic conditions 
to give 22. Carboxylic acid 22 was treated with Ghosez 
reagent17 and coupled with anti-β-hydroxy amino acid 
derivative 23.18 The TBS group was selectively removed 
 
Table 1. Optimization of diastereoselective aldol reaction. 
 
Entry Catalyst Resultsa By-product 
1 Et3N (10 mol%) 50% (dr = 1:1.8) 10% 
2 (S,S)-10a (10 mol%) 64% (dr = 3.1:1) 7% 
3 (S,S)-10b (10 mol%) 77% (dr = 6.5:1) 9% 
4 (S,S)-10b (7 mol%) 80% (dr = 5.0:1) 0% 
5 (R,R)-10b (10 mol%) 80% (dr = 1:>20) 10% 
[a] Diastereomeric ratio (dr) was determined by 1H NMR. 
 
 
and construction of the diazepanone core was extensively 
investigated. The Mitsunobu reaction of 25 using PPh3 and 
di-tert-butyl azodicarboxylate (DBAD) proceeded to give 
the seven-membered ring without epimerization or other 
side reactions. Finally, protecting group manipulation of 26 
gave protected caprazol 6 and the structure was confirmed 
through conversion to caprazol (2).1,7a,8a 
With side chain fragments 4 and 5 and protected 
caprazol 6 in hand, we focused on the introduction of the 
fatty acid side chain. This side chain readily decomposes 
through β-elimination of the β-acyloxy carbonyl under basic 
conditions and cleavage of the O-acylglycoside under acidic 
conditions. In fact, attempts to introduce the fatty acid side 
chain 2719 to model diazepanone 28 using EDCI caused 
β-elimination to give unsaturated carboxylic acid 30 instead 
of desired 29 (Scheme 4). DCC and PyBOP were also 
ineffective. The β-hydroxy ester of diazepanone may also 
decompose through β-elimination and a retro-aldol reaction. 




Scheme 4. Initial attempts to introduce fatty acid side chain (27). 
The final stage of this synthesis began with coupling 
β-siloxy carboxylic acid 4 with protected caprazol 6 without 
epimerization (Scheme 3). The Troc group was removed 
under mild conditions without touching the unstable 
β-acyloxy moiety. This was followed by reductive 
amination. After removal of the TES group, carboxylic acid 
5 was introduced to resultant alcohol 31 using Yamaguchi 
conditions to give protected caprazamycin A (32).8b Finally, 
global deprotection with hydrogenation in the presence of 
Pd black was successful without side-chain decomposition. 
This completed the first total synthesis of caprazamycin A 
(1). The 1H and 13C NMR, IR and HRMS for this matched 
those of the natural product.20 
In summary, we have accomplished the first total 
synthesis of caprazamycin A in 23 steps (longest linear 
sequence from aldehyde 9). The key points are (i) scalable 
synthesis of the syn-β-hydroxy amino acid moiety with a 
thiourea-catalyzed diastereoselective aldol reaction, (ii) 
maintaining the structural integrity of the diazepanone core 
during introduction of the fatty acid side chain, and (iii) 
global deprotection with hydrogenation. This is the first 
report detailing the introduction of the unstable fatty acid 




Scheme 3. Total synthesis of caprazamycin A (1). Reagents and conditions: a) aq. KOH, THF, 0 to 25 °C; b) DBU, THF, 70 °C, 86% (2 steps); c) Zn4(OCOCF3)6O (3.2 mol%), 
MeOH, 50 °C, quant.; d) NaH, pNsCl, DMF, 0 to 25 °C; e) NaOMe, MeOH, 65% (2 steps); f) 21, BF3·Et2O, MS4Å, CH2Cl2, −30 °C, 71%; g) PPh3, THF/PhH = 1:1 then CbzCl, 
aq NaHCO3, 0 to 25 °C; h) Ba(OH)2·8H2O, THF/H2O = 4:1, 0 to 25 °C; i) Ghosez reagent, CH2Cl2, 0 °C then 23, aq. NaHCO3, 0 °C, 46% (3 steps); j) CSA, MeOH/CH2Cl2 = 1:1, 
0 °C, 68% (17% for recovered 24, b.r.s.m. 82%); k) PPh3, DBAD, toluene, 0 °C, 75%; l) K2CO3, PhSH, MeCN, 0 to 25 °C, 73%; m) TrocCl, DMAP, pyridine, CH2Cl2, 0 to 25 °C, 
79%; n) TsOH·H2O, MeOH, 60 °C, 41% and diol having penthylidene acetal (21%); o) CbzCl, DMAP, CH2Cl2, 0 to 25 °C; p) pTsOH·H2O, MeOH, 25 to 60 °C, 71% (2 steps); q) 
4, EDCI, DMAP, CH2Cl2, 0 to 25 °C; r) Zn, AcOH/THF, 25 °C; s) AcOH, ClCH2CH2Cl, 25 °C; t) (CH2O)n, NaBH(OAc)3, AcOH/ClCH2CH2Cl, 25 °C; u) HF·py, THF, 0 °C to 
25 °C, 43% (5 steps); v) 5, 2,4,6- trichlorobenzoyl chloride, DMAP, Et3N, 0 to 25 °C, 64%; w) Pd black, EtOH/HCO2H = 20:1, 25 °C, 98%; x) Zn, AcOH/THF, 25 to 50 °C; y) 
(CH2O)n, NaBH(OAc)3, AcOH/CH2Cl2, 25 °C, quant. (2 steps); z) Pd black, EtOH/HCO2H = 10:1, 25 °C, 46%. DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene, pNs = 
4-nitrobenzenesulfonyl, Ghosez reagent = 1-chloro-N,N,2-trimethylpropenylamine, CSA = 10-camphor sulfonic acid, DBAD = di-tert-butyl azodicarboxylate, TrocCl = 
2,2,2-trichloroethyl chloroformate, DMAP = N,N-dimethyl-4-aminopyridine, Cbz = benzyloxycarbonyl, pTs = p-toluenesulfonyl, EDCI = 1-Ethyl-3- (3-dimethylaminopropyl) 
carbodiimide
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